Oversikt over tumorrettede intervensjonsstudier i Norge åpne for inklusjon – Klikk her
ARIADNE
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
IMPORTANT-studien (EU prosjekt)
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients. Ahus deltar i Norge (PI: Jürgen Geisler)
MK-2870-012 (TROFUSE-012)
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery (OUS, VV Drammen, SUS)
MELODY
Methods for Localization of Different Types of breast lesions (PI: Helle Skjerven)
Intraoperativ strålebehandling av brystkreftpasienter
En kvalitetssikringsstudie (etter Targit studien). PI: Steinar Lundgren.
OPTIMA
OPTIMA (EMIT2). Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Bruk av Prosigna test til adjuvant behandlingsbeslutning. PI: Bjørn Naume.
NAPEER
NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER). An open label phase II trial of endocrine treatment with or without capivasertib, followed by response assessment before neoadjuvant chemotherapy with bevacizumab (if ViRP signature positive).(PI: Olav Engebråten)
TAORMINA
Treatment of Oligometastatic breast cancer – a randomized phase-3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1. line treatment (PI: Vidar Flote)
T-REX
Tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases; an open, multicenter, randomized non-inferiority phase 3-trial (PI: Ingvil Mjaaland)
NBCG 